This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

This study has been withdrawn prior to enrollment.
(Study never moved forward with accrual.)
Information provided by (Responsible Party):
Barbara Ann Karmanos Cancer Institute Identifier:
First received: December 20, 2005
Last updated: April 12, 2013
Last verified: April 2013

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may make tumor cells more sensitive to radiation therapy. Giving gefitinib together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given together with gefitinib and to see how well they work in treating patients with inoperable stage I or stage II non-small cell lung cancer.

Condition Intervention Phase
Non-small Cell Lung Cancer Drug: gefitinib Procedure: adjuvant therapy Procedure: enzyme inhibitor therapy Procedure: neoadjuvant therapy Procedure: protein tyrosine kinase inhibitor therapy Procedure: radiation therapy Procedure: radiosensitization Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Study of Induction Gefitinib and Concurrent Radiotherapy in Patients With Previously Untreated, Medically Inoperable Stage I or II Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Barbara Ann Karmanos Cancer Institute:

Enrollment: 0
Detailed Description:



  • Determine the toxicity profile and maximum tolerated dose of radiotherapy when given in combination with gefitinib in patients with previously untreated, medically inoperable stage I or II non-small cell lung cancer. (Phase I)
  • Determine the efficacy of gefitinib when given for 6 weeks prior to and concurrent with radiotherapy, in terms of objective response rate (partial and complete response), in these patients.


  • Determine the 3-month tumor response (complete and partial response) in patients treated with this regimen.
  • Determine the 6-week response rate in patients treated with this regimen.
  • Determine the local disease control rate (complete and partial response, stable disease) in patients treated with this regimen.
  • Determine the local progression-free survival and disease-specific survival (cancer vs co-morbid disease) of patients treated with this regimen.
  • Determine the pattern of failure (e.g., local, regional, or distant metastasis) in patients treated with this regimen.
  • Determine the acute and late radiation toxic effects to organs at risk in patients treated with this regimen.
  • Determine the safety profile of gefitinib in these patients.

OUTLINE: This is an open-label, multicenter, dose-escalation study of radiotherapy.

  • Patients receive oral gefitinib once daily for 13 weeks. Patients also undergo radiotherapy 5 days a week for 7 weeks beginning at week 7. Patients continue to receive gefitinib alone after completion of radiotherapy in the absence of disease progression or unacceptable toxicity.

Cohorts of 6-10 patients receive escalating doses of radiotherapy until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience acute dose-limiting toxicity.

  • Phase II: Patients receive oral gefitinib as in phase I and radiotherapy at the MTD determined in phase I. After the completion of radiotherapy, patients continue to receive gefitinib in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 1 year.

PROJECTED ACCRUAL: A maximum of 37 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed non-small cell lung cancer (NSCLC)
  • Any non-small cell histology allowed
  • T1-3, N0* disease
  • No metastatic disease
  • Refused or ineligible for surgery
  • Measurable disease, defined as lesion diameter ≤ 5 cm NOTE: *No evidence of N1 or N2 disease by positron emission tomography (PET) scan or any histological means (mediastinoscopy, thoracotomy, transbronchial, tracheal aspirations, or transesophageal aspiration by endoscopic ultrasound guidance


Performance status

  • Any performance status

Life expectancy

  • At least 1 year


  • No restrictions


  • No restrictions


  • Creatinine ≤ CTC grade 2


  • No clinically active interstitial lung disease
  • Chronic, stable, asymptomatic radiographic changes allowed


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective nonhormonal contraception
  • No known severe hypersensitivity to gefitinib or any of the excipients of this product
  • No other malignancy within the past 5 years except basal cell cancer or carcinoma in situ of the cervix
  • No active or uncontrolled infection
  • No uncontrolled systemic disease
  • No psychiatric illness or other severe medical condition that would preclude study participation



  • No prior chemotherapy


  • No prior radiotherapy to the chest or mediastinum
  • No concurrent elective nodal irradiation


  • Recovered from prior surgery
  • No concurrent ophthalmic surgery


  • Recovered from all other prior anticancer therapy (alopecia allowed)
  • More than 30 days since prior nonapproved or investigational agents
  • No concurrent CYP3A4 inducers, including any of the following:
  • Phenytoin
  • Carbamazepine
  • Barbiturates
  • Rifampin
  • Phenobarbital
  • Hypericum perforatum (St. John's wort)
  • No concurrent systemic retinoids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00268255

Sponsors and Collaborators
Barbara Ann Karmanos Cancer Institute
Study Chair: Andrew T. Turrisi, MD Barbara Ann Karmanos Cancer Institute
  More Information

Responsible Party: Barbara Ann Karmanos Cancer Institute Identifier: NCT00268255     History of Changes
Other Study ID Numbers: CDR0000447160
Study First Received: December 20, 2005
Last Updated: April 12, 2013

Keywords provided by Barbara Ann Karmanos Cancer Institute:
stage I non-small cell lung cancer
stage II non-small cell lung cancer
adenosquamous cell lung cancer
bronchoalveolar cell lung cancer
large cell lung cancer
squamous cell lung cancer
adenocarcinoma of the lung

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Enzyme Inhibitors
Antineoplastic Agents
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on July 21, 2017